Dermata Therapeutics, Inc. (DRMA): Total Liabilities
$1.64M
As of 2025-12-31
$1.83M
As of 2026-06-30
+21.1%
3-year compound annual growth
-15.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.64M | -16.8% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $1.97M | +21.5% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $1.62M | +76.0% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $922.6K | -39.2% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $1.52M | -59.9% | 2023-02-21, Balance as of period end |
| 2020-12-31 | $3.78M | n/a | 2022-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $1.64M | -16.8% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $2.24M | +45.9% |
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $2.42M | -25.3% |
| GT Biopharma, Inc. (GTBP) | 2025-09-30 | $1.32M | n/a |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $1.30M | -45.3% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $1.45M | +74.2% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $11.38M | +12.4% |
| Lunai Bioworks Inc. (LNAI) | 2025-06-30 | $29.58M | -5.0% |
| Revium Rx. (RVRC) | 2025-12-31 | $1.42M | +145.7% |
Compare DRMA, PCSA, ACXP, GTBP side by side · Screen every company in Pharmaceutical Preparations ↗